Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07415876 · ClinicalTrials.gov registry record
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA
A clinical trial of Kidney Transplant Rejection, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT07415876: Recruiting study of Kidney Transplant Rejection, sponsored by Virginia Commonwealth University.
NCT07415876 is a study of Kidney Transplant Rejection that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 50 participants, below the 799-participant average among 8 other Kidney Transplant Rejection trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07415876, a study of Kidney Transplant Rejection, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Kidney transplant rejection remains a significant challenge to long-term graft survival. While histological biopsy continues to be the gold standard for diagnosing rejection, noninvasive biomarkers such as donor-derived cell-free DNA (dd-cfDNA) have gained traction for their ability to detect allograft injury. However, dd-cfDNA may lack sensitivity in certain clinical scenarios particularly in cases of localized immune activation leading to false negatives despite biopsy-confirmed rejection.
Primary Outcome
Assess whether urinary CXCL10 concentration (pg/mL) demonstrates improved sensitivity compared to donor-derived cell-free DNA (dd-cfDNA) for diagnosing acute rejection in kidney transplant recipients, specifically among discordant cases with biopsy-confirmed rejection and dd-cfDNA levels below 1%. Urine sample collected prospectively, during clinically indicated biopsy visit. Urine sample collected retrospectively, during clinically indicated retrospective biopsy visit.
Conditions Studied
Interventions
- OTHER Retrospective Cohort Enrollment
- OTHER Prospective Cohort Enrollment
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-01 |
What NCT07415876 shows while recruiting
NCT07415876 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 799-participant average among 8 other Kidney Transplant Rejection trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Kidney Transplant Rejection appearing as the primary indexed condition, and to 2 interventions - of which Retrospective Cohort Enrollment is the first listed.
NCT07415876 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT07415876 about?
NCT07415876 is a clinical study titled "Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA". Kidney transplant rejection remains a significant challenge to long-term graft survival. While histological biopsy continues to be the gold standard for diagnosing rejection, noninvasive biomarkers such as donor-derived cell-free DNA (dd-cfDNA) have gained traction for their ability to detect allogr...
What is the current status of trial NCT07415876?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2026-04. Estimated completion is 2027-01.
What conditions does trial NCT07415876 study?
This clinical trial studies the following conditions: Kidney Transplant Rejection.
What interventions are being tested in trial NCT07415876?
The interventions under investigation include: Retrospective Cohort Enrollment (OTHER), Prospective Cohort Enrollment (OTHER).
Who is sponsoring clinical trial NCT07415876?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07415876 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07415876's enrollment target sits among peer trials
50 7th of 8 higher than 2 of 8 other Kidney Transplant Rejection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplant Rejection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trifecta-Kidney cfDNA-MMDx Study
RECRUITING
-
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
RECRUITING
-
Microbiome and Immunosuppression: The Mission Study
ACTIVE NOT RECRUITING
-
The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
ACTIVE NOT RECRUITING
-
Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection
ACTIVE NOT RECRUITING
-
Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia